Fortrea Holdings (FTRE) Current Deferred Revenue (2022 - 2026)
Fortrea Holdings (FTRE) posted Current Deferred Revenue of $481.3 million for Q1 2026, up 1.58% on a QoQ basis from $473.8 million in Q4 2025, and up 15943.33% year-over-year from N/an in Q1 2025.
Fortrea Holdings (FTRE) Current Deferred Revenue (2022 - 2026) Analysis & Trends
Fortrea Holdings' Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $481.3 million for Q1 2026.
- Quarterly Current Deferred Revenue rose 15943.33% year-over-year to $481.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $481.3 million (up 15943.33% YoY) and the FY2025 annual result came in at $473.8 million, up 34.11% from the prior year.
- Current Deferred Revenue was $481.3 million for Q1 2026 at Fortrea Holdings, up from $473.8 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $481.3 million in Q1 2026 and bottomed at $3.0 million in Q1 2025.
- A 5-year average of $302.0 million and a median of $271.5 million in 2022 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2025 — Current Deferred Revenue sank 98.73% — and 2026, when it jumped 15943.33%.
- Fortrea Holdings' Current Deferred Revenue stood at $271.5 million in 2022, then declined by 21.1% to $214.2 million in 2023, then jumped by 64.94% to $353.3 million in 2024, then jumped by 34.11% to $473.8 million in 2025, then grew by 1.58% to $481.3 million in 2026.
- Business Quant data shows FTRE's Current Deferred Revenue at $481.3 million in Q1 2026, $473.8 million in Q4 2025, and $411.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 481.30 Mn |
| Dec 31, 2025 | 473.80 Mn |
| Sep 30, 2025 | 411.60 Mn |
| Jun 30, 2025 | 381.70 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Dec 31, 2024 | 353.30 Mn |
| Sep 30, 2024 | 321.10 Mn |
| Jun 30, 2024 | 248.00 Mn |
| Mar 31, 2024 | 236.90 Mn |
| Dec 31, 2023 | 214.20 Mn |
| Sep 30, 2023 | 264.80 Mn |
| Jun 30, 2023 | 264.30 Mn |
| Dec 31, 2022 | 271.50 Mn |